AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06028321
Drug: Part 2 Group E (ACM-001.1)
RxNorm normalized name: (E)-2-butenedioic acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Trial: NCT06028321
Drug: Part 2 Group F (ACM-001.1 )
RxNorm normalized name: 2-F-ARAA
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Trial: NCT06246110
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 inhibitor
Trial: NCT06246110
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy
Trial: NCT06246110
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy
Trial: NCT06246110
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT05030519
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
Trial: NCT06566820
Drug: Aroxybutynin and Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination
Trial: NCT04899661
Drug: Molidustat (Musredo, BAY85-3934)
RxNorm normalized name: Molidustat
DrugBank: Molidustat (DB15642)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Tablets, administered orally at the discretion of investigators
Trial: NCT06230757
Drug: Psilocybin 25mg
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg psilocybin capsule
Trial: NCT04938817
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration
Trial: NCT05689645
Drug: Sterilizing water for injection
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days.
Trial: NCT04952753
Drug: NIS793
RxNorm normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
Trial: NCT04952753
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered IV
Trial: NCT04952753
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug tislelizumab will be administered intravenously (IV).
Trial: NCT05938270
Drug: Saruparib (AZD5305)
RxNorm normalized name: Saruparib
DrugBank: Saruparib (DB18982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saruparib (AZD5305) given orally once daily
Trial: NCT05938270
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
Trial: NCT06555796
Drug: Xaluritamig
RxNorm normalized name: Xaluritamig
DrugBank: Xaluritamig (DB18137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05151692
Drug: Nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab will be administered as an IV infusion.
Trial: NCT05439993
Drug: Tepotinib plus paclitaxel
RxNorm normalized name: Tepotinib
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
Trial: NCT05664659
Drug: Oxytocin + misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
Trial: NCT05664659
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms carbetocin
Trial: NCT05282108
Drug: Carcemia
RxNorm normalized name: CARCINIA MANGOSTANA
DrugBank: Mango (DB10657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic Imatinib
Trial: NCT05282108
Drug: Glivec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib
Trial: NCT06074588
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 of docetaxel by IV Infusion
Trial: NCT06074588
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m\^2 of pemetrexed by IV infusion
Trial: NCT04609592
Drug: Lutathera
RxNorm normalized name: Lutathera
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
Trial: NCT04609592
Drug: Gallium 68 Dotatate
RxNorm normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
Trial: NCT05651711
Drug: Rocatinlimab
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocatinlimab will be administered through a subcutaneous (SC) injection.
Trial: NCT06081244
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
Trial: NCT06081244
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg every 3 weeks (q3w)
Trial: NCT05097651
Drug: Cannabidiol oral solution
RxNorm normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
Trial: NCT05097651
Drug: Inert sesame seed oil
DrugBank: Sesame seed (DB10566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
Trial: NCT04916353
Drug: hypertonic dextrose water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% hypertonic dextrose water injection for chronic shoulder pain
Trial: NCT04916353
Drug: Triamcinolone Acetonide.
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone Acetonide 40mg/1ml injection
Trial: NCT00189800
Drug: Solifenacin succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00044837
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06096857
Drug: Roseomonas mucosa (RSM2015) and Cardamom seeds
RxNorm normalized name: Cardamom
DrugBank: Cardamom (DB16576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze dried packet to be reconstituted in water
Trial: NCT06435702
Drug: Darolutamide in addition to androgen deprivation therapy
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
Trial: NCT06788197
Drug: SHR-A1811+ Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular
Trial: NCT06788197
Drug: SHR-A1811+ Fulvestrant+HS-10352
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular ； HS-10351 is administered orally
Trial: NCT04736199
Drug: Darolutamide (Nubeqa, BAY1841788)
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Coated tablet, oral administration
Trial: NCT06461897
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Tablet or Oral Solution
Trial: NCT06461897
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection
Trial: NCT06246643
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
Trial: NCT06131983
Drug: ARO-DUX4 for Injection
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
Trial: NCT05300477
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbonic Anhydrase Inhibitor
Trial: NCT05300477
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone for red blood cell
Trial: NCT06406400
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.
Trial: NCT06406400
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.
Trial: NCT06406400
Drug: Buprenorphine / Naloxone
RxNorm normalized name: buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7
Trial: NCT06406400
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.
Trial: NCT05579132
Drug: CN201
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 7 cycles of maintenance treatment. During the Treatment Period, subjects will receive CN201 by intravenous (IV) infusion once every week (QW), 4 weeks per treatment cycle. The subjects will receive 2 cycles of CN201 for induction. After induction treatment, the drug is discontinued for 2 weeks (treatment-free interval) before consolidation therapy is started, and each subsequent treatment cycle (4 weeks/treatment cycle) is followed by a 2-week treatment-free interval. Responders to induction treatment will continue to receive 3 cycles of consolidation treatment, followed by an additional up to 7 cycles of maintenance treatment, or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first.
Trial: NCT05726032
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
Trial: NCT06646276
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06646276
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05014646
Drug: Cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05014646
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03943901
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab is a monoclonal antibody
Trial: NCT03943901
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy drug, plant alkaloid
Trial: NCT03943901
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid, anti-inflammatory
Trial: NCT05279040
Drug: Trikafta
RxNorm normalized name: Trikafta
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elexacaftor/Tezacaftor/Ivacaftor combination therapy
Trial: NCT05467748
Drug: Tulmimetostat
RxNorm normalized name: Tulmimetostat
DrugBank: Tulmimetostat (DB19446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
Trial: NCT04762992
Drug: subcutaneous Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
Trial: NCT06550076
Drug: TAK-279
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-279 oral tablet
Trial: NCT05242315
Drug: Prograf (SOC)
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prograf (SOC)
Trial: NCT04671836
Drug: Lorazepam 1Mg Tablet
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI.
Trial: NCT05459402
Drug: Methadone (100% dose)
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone for the treatment of opioid use disorder
Trial: NCT05459402
Drug: Methadone (50% dose)
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone for the treatment of opioid use disorder
Trial: NCT06056830
Drug: 64Cu-SAR-bisPSMA
RxNorm normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
Trial: NCT06117306
Drug: 3,4 Methylenedioxymethamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 MDMA session
Trial: NCT05248997
Drug: rimegepant 75 mg ODT
RxNorm normalized name: rimegepant
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of rimegepant 75 mg ODT
Trial: NCT06330064
Drug: Ifinatamab deruxtecan
RxNorm normalized name: Ifinatamab deruxtecan
DrugBank: Ifinatamab deruxtecan (DB18212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT05898412
Drug: Andexanet alfa
RxNorm normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients treated with andexanet alfa
Trial: NCT06289673
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
Trial: NCT06289673
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously (IV) for 1 dose on Day 1 or 2
Trial: NCT06289673
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
Trial: NCT06289673
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
Trial: NCT06289673
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT as part of Intrathecal triple therapy.
Trial: NCT05018286
Drug: Apraglutide
RxNorm normalized name: Apraglutide
DrugBank: Apraglutide (DB18084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
Trial: NCT05655507
Drug: Zuranolone
RxNorm normalized name: Zuranolone
DrugBank: Zuranolone (DB15490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as capsules
Trial: NCT05457283
Drug: Finerenone (Kerendia, BAY94-8862)
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Finerenone in different doses, treatment duration will be 540 ±7 days.
Trial: NCT06107803
Drug: Roluperidone 64 mg
RxNorm normalized name: Domperidone
DrugBank: Roluperidone (DB13080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 mg/day oral
Trial: NCT06107803
Drug: Olanzapine 10 MG
RxNorm normalized name: olanzapine 10 MG
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/day oral
Trial: NCT06356259
Drug: IRX-010
RxNorm normalized name: IRX-2
DrugBank: IRX-2 (DB05643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06038578
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Trial: NCT06038578
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Trial: NCT06445972
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/M\^2 IV infusion
Trial: NCT04724369
Drug: 18F-MFBG
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
Trial: NCT06397703
Drug: Leuprolide, Degarelix or Relugolix
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
Trial: NCT06078592
Drug: Combigan Eye drops
RxNorm normalized name: Combigan
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combigan Eye drops
Trial: NCT06138743
Drug: ARO-DM1 for Injection
RxNorm normalized name: Trastuzumab-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single or multiple doses of ARO-DM1 by intravenous (IV) infusion
Trial: NCT05705258
Drug: Aflibercept (Eylea, BAY86-5321)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist